| __timestamp | Genmab A/S | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 505679000 | 19586000 |
| Thursday, January 1, 2015 | 487656000 | 29135000 |
| Friday, January 1, 2016 | 660876000 | 42791000 |
| Sunday, January 1, 2017 | 874278000 | 49577000 |
| Monday, January 1, 2018 | 1431159000 | 89209000 |
| Tuesday, January 1, 2019 | 2386000000 | 69099000 |
| Wednesday, January 1, 2020 | 3137000000 | 75961000 |
| Friday, January 1, 2021 | 4181000000 | 90467000 |
| Saturday, January 1, 2022 | 5562000000 | 74552000 |
| Sunday, January 1, 2023 | 7630000000 | 91593000 |
| Monday, January 1, 2024 | 9748000000 |
Data in motion
In the ever-evolving world of pharmaceuticals, innovation is the key to staying ahead. Over the past decade, Genmab A/S and Supernus Pharmaceuticals, Inc. have demonstrated contrasting approaches to research and development (R&D) spending. From 2014 to 2023, Genmab A/S has consistently increased its R&D investment, culminating in a staggering 1,400% growth. By 2023, Genmab's R&D expenses reached approximately 7.63 billion, showcasing its commitment to pioneering new treatments. In contrast, Supernus Pharmaceuticals, Inc. has maintained a more conservative approach, with R&D spending peaking at around 91 million in 2023, reflecting a modest 367% increase over the same period. This disparity highlights Genmab's aggressive strategy in prioritizing innovation, while Supernus opts for a more measured path. As the pharmaceutical landscape continues to shift, these strategies will undoubtedly shape the future of healthcare innovation.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Who Prioritizes Innovation? R&D Spending Compared for Biogen Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Genmab A/S and Summit Therapeutics Inc.
Analyzing R&D Budgets: Genmab A/S vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
R&D Insights: How Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Analyzing R&D Budgets: Supernus Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.